Janssen was one of the first companies to recognize the diagnostic and therapeutic potential of monoclonal antibodies, and today we are continuing to apply that expertise to explore their power and promise as targeted, selective cancer therapies.
For example, under a global licensing agreement with Genmab A/S, Janssen is developing a human monoclonal antibody that targets the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Learn more about our licensing agreement with Genmab.
In addition, we are exploring the use of advanced protein engineering technologies to pursue the next generation of human antibody therapeutics in several areas, including bispecific antibodies and alternative scaffolds. Bispecific antibodies are capable of simultaneous binding to two different targets on cancer cells, thus interrupting two molecular pathways leading to cancer cell survival and potentially achieving great gains in therapeutic efficacy. Alternative scaffolds is an emerging class of protein therapeutics that may combine the specificity of monoclonal antibodies with the simplicity, ease of manufacture and tissue penetration associated with small molecules.